Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
Whether intermittent strategies of delivering drugs can improve cancer patients survival is still unclear. Here, the authors reports the results of a randomized phase II clinical trial aimed to compare the efficacy and safety of two dosing regimens (continuous and intermittent) of vemurafenib and co...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/bcf9c314e06143fd83f1b0b564d0166e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:bcf9c314e06143fd83f1b0b564d0166e |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:bcf9c314e06143fd83f1b0b564d0166e2021-12-05T12:23:02ZIntermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial10.1038/s41467-021-26572-62041-1723https://doaj.org/article/bcf9c314e06143fd83f1b0b564d0166e2021-12-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-26572-6https://doaj.org/toc/2041-1723Whether intermittent strategies of delivering drugs can improve cancer patients survival is still unclear. Here, the authors reports the results of a randomized phase II clinical trial aimed to compare the efficacy and safety of two dosing regimens (continuous and intermittent) of vemurafenib and cobimetinib combination as first-line treatment of patients with unresectable or metastatic advanced melanoma with BRAFV600 mutationMaria Gonzalez-CaoClara Mayo de las CasasJuana OramasMiguel A. Berciano-GuerreroLuis de la CruzPablo CerezuelaAna AranceEva Muñoz-CouseloEnrique EspinosaTeresa PuertolasRoberto Diaz BeveridgeSebastian OchenduszkoMaria-Jose VillanuevaLaura BasterretxeaLorena BellidoDelvys RodriguezBegoña CamposClara MontagutAna DrozdowskyjMiguel A. MolinaJose Antonio Lopez-MartinAlfonso BerrocalNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-6 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Maria Gonzalez-Cao Clara Mayo de las Casas Juana Oramas Miguel A. Berciano-Guerrero Luis de la Cruz Pablo Cerezuela Ana Arance Eva Muñoz-Couselo Enrique Espinosa Teresa Puertolas Roberto Diaz Beveridge Sebastian Ochenduszko Maria-Jose Villanueva Laura Basterretxea Lorena Bellido Delvys Rodriguez Begoña Campos Clara Montagut Ana Drozdowskyj Miguel A. Molina Jose Antonio Lopez-Martin Alfonso Berrocal Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial |
| description |
Whether intermittent strategies of delivering drugs can improve cancer patients survival is still unclear. Here, the authors reports the results of a randomized phase II clinical trial aimed to compare the efficacy and safety of two dosing regimens (continuous and intermittent) of vemurafenib and cobimetinib combination as first-line treatment of patients with unresectable or metastatic advanced melanoma with BRAFV600 mutation |
| format |
article |
| author |
Maria Gonzalez-Cao Clara Mayo de las Casas Juana Oramas Miguel A. Berciano-Guerrero Luis de la Cruz Pablo Cerezuela Ana Arance Eva Muñoz-Couselo Enrique Espinosa Teresa Puertolas Roberto Diaz Beveridge Sebastian Ochenduszko Maria-Jose Villanueva Laura Basterretxea Lorena Bellido Delvys Rodriguez Begoña Campos Clara Montagut Ana Drozdowskyj Miguel A. Molina Jose Antonio Lopez-Martin Alfonso Berrocal |
| author_facet |
Maria Gonzalez-Cao Clara Mayo de las Casas Juana Oramas Miguel A. Berciano-Guerrero Luis de la Cruz Pablo Cerezuela Ana Arance Eva Muñoz-Couselo Enrique Espinosa Teresa Puertolas Roberto Diaz Beveridge Sebastian Ochenduszko Maria-Jose Villanueva Laura Basterretxea Lorena Bellido Delvys Rodriguez Begoña Campos Clara Montagut Ana Drozdowskyj Miguel A. Molina Jose Antonio Lopez-Martin Alfonso Berrocal |
| author_sort |
Maria Gonzalez-Cao |
| title |
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial |
| title_short |
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial |
| title_full |
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial |
| title_fullStr |
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial |
| title_full_unstemmed |
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial |
| title_sort |
intermittent braf inhibition in advanced braf mutated melanoma results of a phase ii randomized trial |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/bcf9c314e06143fd83f1b0b564d0166e |
| work_keys_str_mv |
AT mariagonzalezcao intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT claramayodelascasas intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT juanaoramas intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT miguelabercianoguerrero intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT luisdelacruz intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT pablocerezuela intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT anaarance intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT evamunozcouselo intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT enriqueespinosa intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT teresapuertolas intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT robertodiazbeveridge intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT sebastianochenduszko intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT mariajosevillanueva intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT laurabasterretxea intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT lorenabellido intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT delvysrodriguez intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT begonacampos intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT claramontagut intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT anadrozdowskyj intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT miguelamolina intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT joseantoniolopezmartin intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial AT alfonsoberrocal intermittentbrafinhibitioninadvancedbrafmutatedmelanomaresultsofaphaseiirandomizedtrial |
| _version_ |
1718371982195556352 |